Please use this identifier to cite or link to this item:
|Title:||Emerging clinical applications of selected biomarkers in melanoma|
|Authors:||Michael T. Tetzlaff|
Carlos A. Torres-Cabala
Ronald P. Rapini
Victor G. Prieto
Jonathan L. Curry
University of Texas MD Anderson Cancer Center
|Citation:||Clinical, Cosmetic and Investigational Dermatology. Vol.8, (2015), 35-46|
|Abstract:||© 2015 Tetzlaff et al. Melanoma is a lethal skin disease with a mostly predictable clinical course according to a known constellation of clinical and pathologic features. The distinction of melanoma from benign melanocytic nevus is typically unequivocol; however, there is a subset of tumors known for its diagnostic challenges, development of late metastases, and difficulties in treatment. Several melanocytic tissue biomarkers are available that can facilitate the histopathologic interpretation of melanoma as well as provide insight into the biologic potential and mutational status of this disease. This review describes the clinical application of some of these established and emerging tissue biomarkers available to assess melanocytic differentiation, vascular invasion, mitotic capacity, and mutation status. The selected tissue biomarkers in this review include MiTF, Sox10, D2-40, PHH3, H3KT (anti-H3K79me3T80ph), anti-BRAFV600E, and anti-BAP-1.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.